Evidence map›Paper›PMID 41716061›Full record

ReviewCurrent medical imaging2026

Research Progress of MRI-based Radiomics in Rectal Cancer

Liuping Zhu, Yingjie Shao, Wendong Gu

Abstract readReview
In one paragraph

Review in Current medical imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Liuping ZhuDepartment of Radiation Oncology, Changzhou First People's Hospital, Changzhou Medical Center, Nanjing Medical University, Nanjing, Changzhou 213003, China.
Yingjie ShaoDepartment of Radiation Oncology, Changzhou First People's Hospital, Changzhou Medical Center, Nanjing Medical University, Nanjing, Changzhou 213003, China.
Wendong GuDepartment of Radiation Oncology, Changzhou First People's Hospital, Changzhou Medical Center, Nanjing Medical University, Nanjing, Changzhou 213003, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rectal cancer (RC), one of the most common malignant tumors, has a high incidence rate and mortality rate worldwide. Radiomics turns medical images into high-dimensional mineable data through high-throughput extraction algorithms, where the methods include filter-based algorithms and texture analysis. All these features are then combined with machine learning or deep learning algorithms to provide objective evidence to facilitate accurate diagnosis, radiation staging, radiotherapy planning, or prognosis prediction. Multi-parametric magnetic resonance imaging has been considered as one of the best modalities for performing radiomics analysis on rectal cancer because it can capture most features about tumor heterogeneity and micro-environment information. In the past few years, magnetic resonance imaging (MRI)-based radiomics has shown great promise in a variety of fields, including tumor-node-metastasis staging, monitoring pathological high-risk factors, predicting genetic markers, neoadjuvant therapy response evaluation, and prognostic survival analysis in rectal cancer. In this paper, we provide an overview of the current state-of-the-art on MRI radiomics for rectal cancer and present a comparison between the available methods of feature extraction, and provide a critical discussion of current issues and possible developments that might be pursued in future research on this topic.

Indexed as

Magnetic Resonance ImagingRadiomicsRectal NeoplasmsAlgorithmsHumansMachine LearningNeoplasm StagingPrognosisMagnetic resonance imagingMalignant tumorsRadiomicsRectal cancer.Tumor heterogeneityTumor-node-metastasis

Identifiers

PMID41716061
PMCPMC13639913

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.